Skip to main content

Advertisement

SpringerLink
Log in

Effect of cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial

  • Original Article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Gross motor dysfunction is considered as the most challenging problem in cerebral palsy (CP). It is proven that improvement of gross motor function could reduce CP-related disabilities and provide better quality of life in this group of patients. Therefore, the aim of this trial is to evaluate the effectiveness of cerebrolysin (CBL) on gross motor function of children with CP who are undergoing treatment. In this clinical trial study, paediatric patients aged 18–75 months with spastic diplegic or quadriplegic cerebral palsy, who were under rehabilitation therapy, were selected and randomly allocated in control and CBL groups. Patients in CBL group underwent treatment with standard rehabilitation therapy plus CBL. The latter was administrated intramuscularly as a single daily dose of 0.1 cc/kg for 10 days and then continued weekly for 4 months. Gross motor function of participants in the two studied groups, before and after trial, was evaluated and compared using the validated Persian version of gross motor function classification system-expanded and revised (GMFCS-E&R). During this trial, 108 patients with CP were evaluated for eligibility. From these, 50 patients were enrolled and randomly allocated in the CBL and control groups. Four months after trial, the mean level of GMFCS decreased significantly in the two groups (P < 0.05). However, it was significantly lower in the CBL group than in the control group (2.1 vs. 3.16, P < 0.05). The results of this trial indicated that CBL could improve gross motor function in patients with CP. This finding is consistent with neurotrophic and neuroprotective effects of CBL, which have been reported in various clinical trials in other neurological disorders. Further studies are recommended to establish the value of continued neuroprotection and to determine the pharmacokinetics/dynamics of CBL in this group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jones MW, Morgan E, Shelton JE, Thorogood C (2007) Cerebral palsy: introduction and diagnosis (part I). J Pediatr Health Care Off Publ Natl Assoc Pediatr Nurse Assoc Pract 21(3):146–152

    Google Scholar 

  2. Shevell MI, Bodensteiner JB (2004) Cerebral palsy: defining the problem. Sem Pediatr Neurol 11(1):2–4

    Article  Google Scholar 

  3. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B et al (2005) Proposed definition and classification of cerebral palsy. Dev Med Child Neurol 47(8):571–576

    Article  PubMed  Google Scholar 

  4. Odding E, Roebroeck ME, Stam HJ (2006) The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil 28(4):183–191

    Article  PubMed  Google Scholar 

  5. Miller F (2005) Cerebral palsy. Springer Science-Business Media, New York, pp 523–666

    Google Scholar 

  6. labaf S, Shamsoddini A, Hollisaz MT, Sobhani V, Shakibaee A (2015) Effects of neurodevelopmental therapy on gross motor function in children with cerebral palsy. Iran J Child Neurol 9(1):36–41

    PubMed  PubMed Central  Google Scholar 

  7. Shamsoddini A, Amirsalari S, Hollisaz MT, Rahimnia A, Khatibi-Aghda A (2014) Management of spasticity in children with cerebral palsy. Iran. J Pediatr 24(4):345–351

    Google Scholar 

  8. Wittenberg GF (2010) Experience, cortical remapping, and recovery in brain disease. Neurobiol Dis 37(2):252–258

    Article  PubMed  Google Scholar 

  9. Carroll JE, Mays RW (2011) Update on stem cell therapy for cerebral palsy. Expert Opin Biol Ther 11(4):463–471

    Article  PubMed  PubMed Central  Google Scholar 

  10. Balakrishnan B, Nance E, Johnston MV, Kannan R, Kannan S (2013) Nanomedicine in cerebral palsy. Int J Nanomed 8:4183–4195

    Google Scholar 

  11. Aisen ML, Kerkovich D, Mast J, Mulroy S, Wren TA, Kay RM, Rethlefsen SA (2011) Cerebral palsy: clinical care and neurological rehabilitation. Lancet Neurol 10(9):844–852

    Article  PubMed  Google Scholar 

  12. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M et al (2006) A 24-week, double-blind, placebo-controlled study of three dosages of cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol Off J Eur Fed Neurol Soc 13(1):43–54

    CAS  Google Scholar 

  13. Rockenstein E, Adame A, Mante M, Larrea G, Crews L, Windisch M et al (2005) Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer’s disease with the neurotrophic compound cerebrolysin. J Neural Transm 112(2):269–282

    Article  CAS  PubMed  Google Scholar 

  14. Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, Tahamtan U, Rezaei Y (2014) Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatr Dis Treat 10:2299–2306

    PubMed  PubMed Central  Google Scholar 

  15. Zhang Y, Chopp M, Meng Y, Zhang ZG, Doppler E, Winter S et al (2015) Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury. J Neurosurg 122(4):1–13

    Google Scholar 

  16. Masliah E, Diez-Tejedor E (2012) The pharmacology of neurotrophic treatment with cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc) 48(Suppl A):3–24

    CAS  Google Scholar 

  17. Chen N, Yang M, Guo J, Zhou M, Zhu C, He L (2013) Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 1:CD008900

    Google Scholar 

  18. Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E et al (2011) Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of cerebrolysin. Eur J Neurol Off J Eur Fed Neurol Soc 18(1):59–68

    CAS  Google Scholar 

  19. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z (2012) Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke J Cereb Circ 43(3):630–636

    Article  CAS  Google Scholar 

  20. Thome J, Doppler E (2012) Safety profile of cerebrolysin: clinical experience from dementia and stroke trials. Drugs Today (Barc) 48(Suppl A):63–69

    CAS  Google Scholar 

  21. Dehghan L, Dalvand H, Abdolvahab M, Bagheri H, Faghih zade S (2011) Inter rater reliability of Persian version Gross Motor Function Classification System Expanded & Revised in patients with cerebral palsy. Bimonthly Official Publication Medical Daneshvar 18(91):37–44

  22. Sharma HS, Muresanu DF, Patnaik R, Stan AD, Vacaras V, Perju-Dumbrav L et al (2011) Superior neuroprotective effects of cerebrolysin in heat stroke following chronic intoxication of Cu or Ag engineered nanoparticles. A comparative study with other neuroprotective agents using biochemical and morphological approaches in the rat. J Nanosci Nanotechnol 11(9):7549–7569

    Article  CAS  PubMed  Google Scholar 

  23. Young W (2009) Cerebrolysin Review. Available from https://wiseyoung.wordpress.com/2009/02/10/271/. Accessed 22 Dec 2016

  24. Lukhanina EP, Karaban IN, Burenok Iu A, Mel’nik NA, Berezetskaia NM (2004) Zhurnal nevrologii i psikhiatrii imeni SS Korsakova/Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson’s disease] [i] Vserossiiskoe obshchestvo psikhiat 104(7):54–60

  25. Doppler E, Rockenstein E, Ubhi K, Inglis C, Mante M, Adame A et al (2008) Neurotrophic effects of cerebrolysin in the Mecp2 (308/Y) transgenic model of Rett syndrome. Acta Neuropathol 116(4):425–437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hutter-Paier B, Steiner E, Windisch M (1998) Cerebrolysin protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia. J Neural Transm Suppl 53:351–361

    Article  CAS  PubMed  Google Scholar 

  27. Hutter-Paier B, Fruhwirth M, Grygar E, Windisch M (1996) Cerebrolysin protects neurons from ischemia-induced loss of microtubule—associated protein 2. J Neural Transm Suppl 47:276

    Article  CAS  PubMed  Google Scholar 

  28. Ruther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27(1):32–40

    Article  CAS  PubMed  Google Scholar 

  29. Allegri RF, Guekht A (2012) Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia. Drugs Today (Barc) 48(Suppl A):25–41

    CAS  Google Scholar 

  30. Gershman RN, Vasilenko MA (1975) Use of cerebrolysin and ATP in treating infantile cerebral paralysis. Pediatr Akus Ginekol (1):22–23 (Article in Ukrainian)

  31. Petrukhin AS, Pylaeva OA (2014) Cerebrolysin in pediatric neurology practice. Zh Nevrol Psikhiatr Im S S Korsakova 114(1 Pt 2):75–80 (Article in Russian)

  32. Hong Z, Moessler H, Bornstein N, Brainin M, Heiss WD, Investigators C (2009) A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia–CASTA. Int J Stroke Off J Int Stroke Soc 4(5):406–412

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Neurology, Faculty of Medicine and Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    Jafar Nasiri & Faezeh Safavifar

Authors
  1. Jafar Nasiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faezeh Safavifar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jafar Nasiri.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The protocol of the study was approved by the Pediatrics Review Board and the Regional Ethics Committee of Isfahan University of Medical Sciences (Research Project Number: 393470).

Informed consent

Written informed consent was obtained from the parents of selected patients after describing the goal of and treatments in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nasiri, J., Safavifar, F. Effect of cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial. Acta Neurol Belg 117, 501–505 (2017). https://doi.org/10.1007/s13760-016-0743-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-016-0743-x

Keywords

Search

Navigation